PubMed · 2006 · 182 citations · 14 references
MedicineNeurologyPharmacologyDementiaNeuropharmacologyPsychopharmacologyDeep Brain StimulationNeurodegenerative Disease PharmacotherapyNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseParkinsonian DisordersCatechol-o-methyltransferase InhibitionDopamine Receptor AgonistsDyskinesia ReductionMonoamine Oxidase InhibitorsParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease TreatmentSubthalamic Nucleus Physiology
Parkinson's disease is a common neurodegenerative disorder that can cause significant disability and decreased quality of life. The cardinal physical signs of the disease are distal resting tremor, rigidity, bradykinesia, and asymmetric onset. Levodopa is the primary treatment for Parkinson's disease; however, its long-term use is limited by motor complications and drug-induced dyskinesia. Dopamine agonists are options for initial treatment and have been shown to delay the onset of motor complications. However, dopamine agonists are inferior to levodopa in controlling motor symptoms. After levodopa-related motor complications develop in advanced Parkinson's disease, it is beneficial to initiate adjuvant therapy with dopamine agonists, catechol O-methyltransferase inhibitors, or monoamine oxidase-B inhibitors. Deep brain stimulation of the subthalamic nucleus has been shown to ameliorate symptoms in patients with advanced disease. Depression, dementia, and psychosis are common psychiatric problems associated with Parkinson's disease. Psychosis is usually drug induced and can be managed initially by reducing antiparkinsonian medications. The judicious use of psychoactive agents may be necessary. Consultation with a subspecialist is often required.
14
Olivier Rascol, David J. Brooks, Amos D. Korczyn et al. · New England Journal of Medicine · 2000 · 1.5K citations · Full text
Medicine, Neurology, Pharmacotherapy +11
Prevalence and Characteristics of Dementia in Parkinson Disease
Dag Aarsland, Kjeld Andersen, Jan Larsen et al. · Archives of Neurology · 2003 · 1.4K citations
Effects of Coenzyme Q10 in Early Parkinson Disease
Clifford W. Shults · Archives of Neurology · 2002 · 977 citations
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Alan Whone, Ray L. Watts, A. Jon Stoessl et al. · Annals of Neurology · 2003 · 828 citations
Medicine, Neurology, Pharmacology +17
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Robert G. Holloway, Ira Shoulson, Karl Kieburtz et al. · JAMA · 2000 · 802 citations
Medicine, Neurology, Pharmacotherapy +12